CVS Health Earnings Call Transcripts
Fiscal Year 2026
-
The planned separation is intended to create two investment-grade businesses with independent growth paths, with ongoing dis-synergies expected nearer $500 million than estimates above $1 billion. Retail pharmacy targets reimbursement stabilization and adjacent-service growth, while Medicare and PBM recovery continue through 2027-28.
-
Q3 adjusted EPS was $2.09, up over 30% YoY, and FY 2026 adjusted EPS guidance rose to at least $8.20. A planned H1 2028 separation will create an integrated healthcare solutions business and CVS Pharmacy, with 2027 adjusted EPS expected at least $8.65.
-
Momentum is strong across health plan, pharmacy, and healthcare delivery, with disciplined execution driving margin recovery and growth. Cost management, innovation, and technology investments are improving efficiency and outcomes, while capital deployment is set to support further growth and shareholder returns.
-
Q2 2026 saw broad-based revenue and earnings growth, with adjusted EPS up 40% and all segments outperforming. Full-year guidance was raised for EPS and cash flow, driven by strong pharmacy, health services, and benefits results, despite ongoing 340B and reimbursement headwinds.
-
The meeting approved all management proposals, including director elections and executive compensation, while a shareholder proposal to lower the written consent threshold was rejected. Strong financial results and ongoing strategic initiatives in technology, affordability, and healthcare delivery were highlighted.
-
Q1 2026 saw strong revenue and earnings growth, with adjusted EPS up 14% and full-year guidance raised. Segment performance was robust, especially in Health Care Benefits and value-based care, while investments in technology and regulatory adaptation remain key priorities.
-
Leadership is integrating pharmacy, PBM, and care delivery to create a seamless consumer experience, leveraging technology, acquisitions, and new reimbursement models. Regulatory changes are being proactively addressed, while digital transformation through Health100 aims to enhance engagement and affordability.
Fiscal Year 2025
-
Full year 2025 revenue exceeded $400 billion with strong EPS and cash flow, driven by robust performance across all segments and successful integration of Rite Aid assets. 2026 guidance is reaffirmed, with continued focus on margin recovery, operational excellence, and technology investment.
-
The company outlined a bold transformation to become the most trusted healthcare provider, leveraging technology, operational rigor, and a new Consumer Engagement Platform. Financial guidance calls for mid-teens EPS CAGR through 2028, with growth across all segments and significant cash generation.
-
Q3 saw record revenue and strong EPS growth, prompting a raised full-year outlook. All segments contributed, with notable gains in pharmacy and consumer wellness, but a $5.7B goodwill impairment was recorded in healthcare delivery. 2026 guidance anticipates mid-teens EPS growth.
-
Q2 2025 saw strong revenue and earnings growth, with adjusted EPS guidance raised to $6.30-$6.40. Healthcare benefits and pharmacy segments outperformed, while Healthcare delivery faced margin pressure from Oak Street. The company remains focused on innovation, cost management, and disciplined capital allocation.
-
Q1 2025 saw strong revenue and earnings growth, with all segments contributing and full-year EPS guidance raised. The company is exiting the ACA exchange business, expanding access to Wegovy, and maintaining a cautious outlook amid cost and regulatory pressures.
Fiscal Year 2024
-
Q4 2024 saw adjusted EPS of $1.19 and revenues up 4% year-over-year, with strong growth in Health Care Benefits and Pharmacy & Consumer Wellness. 2025 guidance projects adjusted EPS of $5.75–$6, driven by Aetna recovery and Health Services growth, while cost and membership pressures persist.
-
Leadership changes and new board members are driving strategic shifts, including pricing model innovations. Financial performance is stabilizing, with cautious outlooks for 2024 and 2025 amid cost and membership variability. Pharmacy and health services are transitioning to new models for improved transparency and profitability.
-
Third quarter revenue grew 6% to $95.4B, but healthcare benefits posted a loss due to high utilization and PDRs. No formal 2024 guidance was given, but margin recovery is expected in 2025 as benefit and pricing changes take effect.
-
Q2 2024 saw $91.2B in revenue and $1.83 adjusted EPS, with strong pharmacy and health services offsetting healthcare benefits pressure. 2024 EPS guidance was lowered, but 2025 margin recovery and productivity initiatives are expected to drive improvement.
Fiscal Year 2023
Fiscal Year 2022
-
All three operating segments performed at or above expectations in 2022, while 2024 Star Ratings and contract losses create a ~$2 billion headwind. Signify was expected to support 2024 growth, with mitigation and share repurchases among the response options.
-
Q2 revenue rose 11% YoY, with strong cash flow and higher EPS guidance. Signify is intended to expand in-home and value-based care, while stable utilization and a multi-year biosimilar opportunity shaped the outlook.
-
Growth plans balance acquisitions with existing-business improvement, while primary care, MSO capabilities and home health remain strategic priorities. Retail faces reimbursement pressure, and Caremark growth may benefit from specialty generics and biosimilars over the next two to three years.
-
Q1 started strongly, while COVID effects continued to offset across insurance and retail. Plans center on connected care and digital convenience; Medicare Advantage remained favorable, and retail reimbursement and Medicaid RFP wins were key execution priorities.
-
COVID trends remained volatile, with retail and HCB effects offsetting; store closures were framed as de-densification, while MA growth and mid-single-digit margins remained priorities. Biosimilars and capability-focused M&A were identified as longer-term opportunities.
-
FY2021 adjusted EPS guidance rose to $8.33-$8.38, with at least $13.5B in expected cash flow. Strategy centers on risk-based primary care, digital and omnichannel services, supporting low-double-digit adjusted EPS growth from 2024.
Fiscal Year 2021
-
Strategy is shifting toward integrated, payer-agnostic care delivery, with advanced primary care, virtual and home care among the priorities. COVID, capital deployment, and portfolio choices are key factors for 2022 and beyond.
-
The integrated model combines insurance, pharmacy, retail, virtual, and clinical care, with Q2 2021 revenue growth of 11% and operating cash flow of $5.8 billion. 2022 priorities included Medicare and service expansion, investment in care capabilities, and balancing growth with reimbursement and labor-cost pressures.
-
Priorities include integrated health services, digital care and growth in Medicare Advantage and individual markets. PBM earnings are expected to moderate in 2H 2021, while retail, testing and vaccine assets support care delivery.
-
9M 2020 revenue rose ~5% and operating cash flow reached $12.3B, while pandemic response accelerated digital and community-based care. Vaccination capacity, HealthHUB expansion, and continued deleveraging underpin the forward strategy.
Fiscal Year 2020
-
FY2020 guidance rose after strong YTD performance, while vaccine readiness supported capacity of 20M–25M doses monthly. Incoming CEO Karen Lynch plans to focus on innovation, personalized medicine and digital capabilities.
-
COVID accelerated community, home and virtual care, with more than 3 million tests and rapid E-Clinic growth. FY2020 adjusted EPS guidance held at $7.14-$7.27; HealthHUB expansion remained on track for 1,500 locations by end-2021.
-
Q1 revenue grew 8.3% and adjusted EPS 17.9%, while FY2020 guidance remained unchanged amid pandemic uncertainty. Testing, integrated care, and HealthHUBs were key strategic priorities; utilization and enrollment trends remained uneven.
-
COVID-19’s financial impact was difficult to quantify, while pharmacy supply remained stable and care-access measures were expanded. HealthHUBs, higher merger synergy expectations and Medicare Advantage growth supported the outlook; FY2020 adjusted EPS guidance remained $7.04–$7.17.
-
Plans called for 1,500 HealthHUBs by end-2021, while integration synergies were projected to reach $800 million in 2020. Adjusted 2020 EPS was expected to be at least $7, and a home hemodialysis device could reach market in H2 2021 if successful.
Fiscal Year 2019
-
Integration synergies are expected to reach $800M in 2020 and a $900M run rate in 2021, alongside a HealthHUB rollout to 1,500 locations by end-2021. 2020 expectations remain at least $7 adjusted EPS, with a low-3x adjusted debt/EBITDA target by 2022.
-
Early post-merger progress included strong Q2 results, HealthHUB traction and disciplined medical cost management. Priorities included nationwide CarePass rollout in Q4 2019, faster-than-market Medicare Advantage growth in 2020, and ~$800 million in 2020 synergies.
-
Integration synergies were ahead of the initial $750M target, while HealthHUB pilots showed encouraging early engagement. 2019 priorities included PBM transitions, MA and commercial growth, and retail script growth of 4.5%–6.8%.
-
2019 pressures include pharmacy margin compression and rebate guarantees, which peak this year and ease in 2020. Integration, new contracting, selective HealthHUB expansion and care-delivery tools are key growth and savings opportunities.
-
Aetna integration targets >$750M in 2020 synergies and broader medical-cost savings.
Fiscal Year 2018
-
The merger was expected to close on Nov. 28, 2018, with near-term integration and >$750M in synergies in the second full year. Longer-term plans center on care-coordination pilots, local services and lower medical costs.
-
Integration targeted $750 million in synergies by the second full year after close, with closing expected by early Q4 2018. Priorities included drug-cost reduction, consumer-centered care, omnichannel pharmacy and expanded clinic services.
-
FY 2018 adjusted operating profit growth was projected at 1%-4%, with revenue growth of 0.75%-2.5%. Script growth and tax reform were expected to support results, offset by Anthem implementation, RxCrossroads and financing effects.
Fiscal Year 2017
-
Q4 revenue and adjusted operating profit grew, and adjusted EPS rose 12% to $1.92, while FY adjusted operating profit declined 5.8%. 2018 guidance includes reinvestment of tax savings, debt reduction, and continued preparation for the planned Aetna transaction.
-
The deal combines pharmacy, medical benefits, and community care in a consumer-focused platform, with a $77B transaction value and H2 2018 close target. Management expects $750M in synergies and low- to mid-single-digit accretion in the second full year after closing.
-
Q3 revenue grew 3.5% and adjusted EPS reached $1.50, while adjusted operating profit declined 13.1%. FY17 adjusted EPS guidance narrowed with a higher midpoint; hurricane costs, reimbursement pressure and Medicare Part D timing shaped results and outlook.
-
PBM wins and renewals underscored demand for cost management, while integrated clinical, pharmacy and payer capabilities supported growth. 2017 earnings were expected to skew to H2 as Part D utilization and generic timing shifted profits.
-
Q2 revenue rose 4.5% and adjusted EPS reached $1.33, while adjusted operating profit fell 7%. FY17 adjusted EPS guidance was narrowed and its midpoint raised, supported by cash generation and buybacks despite softer retail volumes.
-
Pharmacy’s regulated, insurance-linked model and pharmacist relationships were presented as differentiators from e-commerce; mail order accounted for <15% of prescriptions and was declining. Integrated clinical programs target better outcomes and lower costs, while SilverScript had 5.5M members and a four-star rating for two years.
-
Revenue rose 3% and adjusted EPS reached $1.17, ahead of guidance, while margins and retail sales remained pressured. FY17 EPS guidance was maintained, with substantial shareholder returns and a back-half-weighted profit cadence expected.
-
Client drug cost trend was a little over 3% YoY, while integrated pharmacist and specialty services supported health plan growth. Long-term top-line growth aspiration was about 11%, with the generic pipeline expected to exert less drag over the next five years.
-
Integrated pharmacy, payer and care assets were positioned to lower costs and improve outcomes, with PBM membership nearing 90M in 2017. A multi-year efficiency plan targets nearly $3B in cumulative savings by 2021, alongside a long-term adjusted EPS growth target of roughly 10% on average.
Fiscal Year 2016
-
FY16 revenue and adjusted EPS grew strongly, while 2017 guidance called for a rebuilding year with softer revenue and lower operating profit. Free cash flow remained substantial, supporting planned shareholder returns above $7B in 2017.
-
2017 guidance reflects prescription losses, slower acquisition accretion, and margin pressure, while long-term EPS growth is targeted at ~10% on average. Partnerships, new offerings, and a five-year $3B savings plan underpin the return to growth.
-
Q3 adjusted EPS rose 28% to $1.64, while new network restrictions and retail pressures lowered FY16 guidance. FY17 adjusted EPS is projected at $5.77-$5.93; management targets ~10% average long-term growth and $7B-$8B annual free cash flow.
-
PBM tools held 2016 YTD drug trend to 3.5% YoY versus inflation above 9%, with more than $9B in client savings projected for 2012–17. Selling season wins, growing health plan business and integrated care capabilities supported the growth outlook; capital priorities included a 2018 dividend payout target and annual buybacks of $4B–$5B.
-
Q2 adjusted EPS rose 8.3% to $1.32, while operating profit grew 6.5% excluding acquisition costs. FY16 adjusted EPS guidance rose to $5.81-$5.89 and free cash flow guidance to $6.3B-$6.6B.
-
2016 earnings were on plan, with delivery weighted to H2 through Part D growth, generic launches, repurchases, and tax benefits. Longer-term growth priorities included procurement and operating efficiency, acquisitions, and dispensing-share gains.
-
The integrated model supported PBM wins, specialty growth, and expansion into retail clinics and long-term care. 2016 adjusted EPS guidance was $5.73-$5.88, with more than $5B planned for dividends and buybacks.
-
Adjusted EPS rose 4% to $1.18 and revenue grew 18.9% to $43.2B, with PBM volume and purchasing economics driving outperformance. FY adjusted EPS guidance was reaffirmed, while retail revenue growth guidance was reduced and shareholder returns remained substantial.